International Journal of Cardiology
Volume 129, Issue 3 , Pages 379-387, 13 October 2008

Predictors of outcome in patients undergoing PCI. Results of the RIVIERA study☆☆☆

  • Gilles Montalescot

      Affiliations

    • Institut de Cardiologie, Pitié-Salpêtrière Hospital, Paris, France
    • Corresponding Author InformationCorresponding author. Gilles Montalescot, Institut de Cardiologie, Bureau 2-236, Centre Hospitalier Universitaire Pitié-Salpêtrière, 47 Blvd de l'Hôpital, 75013, Paris, France. Tel.: +33 1 42 16 30 06; fax: +33 1 42 16 29 31.
    • ,
  • Zeki Öngen

      Affiliations

    • Cerrahpaşa Medical Faculty, Istanbul University, Istanbul, Turkey
    • ,
  • Ramez Guindy

      Affiliations

    • Cairo Special Hospital, Cairo, Egypt
    • ,
  • Amanda Sousa

      Affiliations

    • Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil
    • ,
  • Shu-Zheng Lu

      Affiliations

    • Beijing Anzhen Hospital, Beijing, PR China
    • ,
  • Dev Pahlajani

      Affiliations

    • Kirti Manor, Breach Candy Hospital, Mumbai, India
    • ,
  • André Pellois

      Affiliations

    • sanofi-aventis, Paris, France
    • ,
  • Eric Vicaut

      Affiliations

    • Unité de Recherche Clinique, Hôpital Lariboisière, Paris, France
    • ,
  • for the RIVIERA Investigators

Received 26 February 2007; received in revised form 7 June 2007; accepted 7 July 2007. published online 06 December 2007.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

☆ Grant support: The RIVIERA study is funded by sanofi-aventis, Paris, France.

☆☆ The authors all served on the advisory board of the RIVIERA registry. In addition, Gilles Montalescot has received research grants from sanofi-aventis, Eli Lilly and Guerbet; honoraria from sanofi-aventis, Eli-Lilly, GSK, MSD, The Medicine's Company, and Pfizer, and has been consulted/on advisory boards for sanofi-aventis, Eli-Lilly, GSK, MSD, The Medicine's Company, Schering Plough, and Pfizer; Andre Pellois was an employee of sanofi-aventis; Amanda Sousa had received enoxaparin.

PII: S0167-5273(07)01714-7

doi:10.1016/j.ijcard.2007.07.127

International Journal of Cardiology
Volume 129, Issue 3 , Pages 379-387, 13 October 2008

Article Tools

* Image Usage & Resolution